Fosså, Alexander <br/><br/>
Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016.  [electronic resource] 

 -  Acta oncologica (Stockholm, Sweden)  Jan 2020 
 - 101-105 p.  digital 
<br/><br/> Publication Type: Letter; Multicenter Study 
<br/><br/><label>ISSN: </label>1651-226X 
<br/><br/><label>Standard No.: </label>10.1080/0284186X.2019.1652765  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Allografts<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Brentuximab Vedotin--therapeutic use<br/>Female<br/>Hodgkin Disease--mortality<br/>Humans<br/>Male<br/>Middle Aged<br/>Norway<br/>Recurrence<br/>Stem Cell Transplantation<br/>Survival Analysis<br/>Transplantation, Autologous<br/>Treatment Outcome